Viamet announced that the FDA has granted Orphan Drug designation to VT-1129, a selective oral antifungal agent, for the treatment of cryptococcal meningitis.
In preclinical studies, VT-1129 has been shown to be a potent and selective, orally available inhibitor of fungal CYP51. VT-1129 blocks the production of ergosterol, an essential component of the fungal cell membrane, which is critical to fungal proliferation and survival. Additionally, VT-1129 has demonstrated substantial potency against Cryptococcus species and high concentrations within the central nervous system in preclinical studies.
The company plans on submitting an Investigational New Drug (IND) Application for VT-1129 to the FDA during the first half of 2015.
For more information visit Viamet.com.